2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis
International Journal of Clinical Oncology · 2024-07 · 29 (7) · 873-888
DOI: 10.1007/s10147-024-02535-x ↗Kurz gefasst
Leitlinie in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 16.05.2024. Verfasst von Hirotoshi Iihara und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. Hauptthemen laut MEDLINE: Medical Oncology, Antiemetics, Vomiting. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest advances in antineoplastic agents, antiemetics, and antineoplastic regimens. This update provides new evidence on the efficacy of antiemetic regimens.
Methods
Guided by the Minds Clinical Practice Guideline Development Manual of 2017, a rigorous approach was used to update the guidelines; a thorough literature search was conducted from January 1, 1990, to December 31, 2020.
Results
Comprehensive process resulted in the creation of 13 background questions (BQs), 12 clinical questions (CQs), and three future research questions (FQs). Moreover, the emetic risk classification was also updated.
Conclusions
The primary goal of the present guidelines is to provide comprehensive information and facilitate informed decision-making, regarding antiemetic therapy, for both patients and healthcare providers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
- Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
- Department of Psycho‑Oncology and Palliative Medicine, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka, Osaka, 541-8567, Japan.
- School of Nursing, National College of Nursing, Japan, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.
- Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
- Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8555, Japan.
Zitieren
APA
Iihara, H., Abe, M., Wada, M., Iino, K., Akechi, T., Imamura, C. K., Okuyama, A., Ozawa, K., Kim, Y. I., Sasaki, H., Satomi, E., Takeda, M., Tanaka, R., Nakajima, T. E., Nakamura, N., Nishimura, J., Noda, M., Hayashi, K., Higashi, T., …, & Aogi, K. (2024). 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. International Journal of Clinical Oncology, 29(7), 873-888. https://doi.org/10.1007/s10147-024-02535-x
Vancouver
Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, et al. 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. International Journal of Clinical Oncology. 2024;29(7):873-888. doi:10.1007/s10147-024-02535-x
BibTeX
@article{Iihara2024,
author = {Iihara, Hirotoshi and Abe, Masakazu and Wada, Makoto and Iino, Keiko and Akechi, Tatsuo and Imamura, Chiyo K and Okuyama, Ayako and Ozawa, Keiko and Kim, Yong-Il and Sasaki, Hidenori and Satomi, Eriko and Takeda, Masayuki and Tanaka, Ryuhei and Nakajima, Takako Eguchi and Nakamura, Naoki and Nishimura, Junichi and Noda, Mayumi and Hayashi, Kazumi and Higashi, Takahiro and Boku, Narikazu and Matsumoto, Koji and Matsumoto, Yoko and Okita, Kenji and Yamamoto, Nobuyuki and Aogi, Kenjiro},
title = {2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis},
journal = {International Journal of Clinical Oncology},
year = {2024},
volume = {29},
number = {7},
pages = {873--888},
doi = {10.1007/s10147-024-02535-x}
}
EUVIMED